Menopause
From the Journals
Early menopause linked with increased risk of heart problems
A study of more than 1.4 million women revealed that the younger the age at menopause, the higher the risk of heart failure and atrial...
Clinical Review
How should you advise your 54-year-old patient about the use of HT?
And how would your recommendations change if she has certain cardiovascular or breast cancer risk factors?
Latest News
Does cannabis help with menopause symptoms?
Women with symptoms of menopause are turning to cannabis for help, researchers have found, despite a lack of evidence that the drug works for...
Guidelines
NAMS affirms value of hormone therapy for menopausal women
Recent research supports individualized care to maximize benefits and minimize risks.
Latest News
Routine weight counseling urged for women at midlife
“Midlife women gain weight at an average of approximately 1.5 pounds per year, which increases their risk for transitioning from normal or...
Latest News
Hormone therapy didn’t increase recurrence or mortality in women treated for breast cancer
Recurrence was increased with vaginal hormone therapy among those taking aromatase inhibitors.
Clinical Review
2022 Update on menopause
A review of new evidence on risks of synthetic progestins in menopausal women at average risk for breast cancer, advantages of...
Latest News
Hormone therapy and breast cancer: An overview
It can be expected that the effects of menopausal hormone therapy may vary between participants on the basis of age or time since menopause, as...
Conference Coverage
COVID-19 Pandemic stress affected ovulation, not menstruation
The ‘experiment of nature’ that coincided with the COVID-19 pandemic lockdown produced several findings that call into question commonly held...
From the Journals
Why do we treat menopause as a disease?
Over centuries society and medicine have emphasized the negative aspects, and authors of a new analysis say this has eaten away at women’s...
Conference Coverage
Nonhormonal drug for menopause symptoms passes phase 3 test
The novel NK3 receptor–inhibitor fezolinetant controlled vasomotor symptoms of menopause over 52 weeks in the phase 3 SKYLIGHT 2 trial.